Altus Capital Partners
VC Fund
Wilton, United States
Altus Capital Partners is a VC fund in Wilton focused on Health Care and Therapeutics. Altus Capital Partners is recognized for its deep knowledge and commitment to American manufacturers with proprietary technologies. They have a proven track record in building value through buyouts, recapitalizations, divestitures and consolidations.
- Total investments:
- 1
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Altus Capital Partners invests in
Stages Altus Capital Partners invests in
Countries Altus Capital Partners invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Joshua Tesoriero
|
|||
Nick DeMarco
|
|||
Tom Groh
|
|||
Investment Focus
Industry
- Health Care 1 (100%)
- Therapeutics 1 (100%)
- Pharmaceutical 1 (100%)
- Health Diagnostics 1 (100%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Joshua Tesoriero
Vice President
|
Vice President | Total investments: 0 | Find email | |
|
Nick DeMarco
Principal
|
Principal | Total investments: 0 | Find email | |
|
Tom Groh
Partner
|
Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Versantis
|
Versantis is a Swiss pharmaceutical company, Spin-off of ETH Zurich, developing a new generation of medicines and diagnostics to revolutionize the care of patients with liver disease. Embracing lifesaving and preventive therapies, Versantis aims to answer the unmet medical need of millions of people worldwide. Its lead candidate, VS-01, iscurrently at preclinical stage and has the potential to be the first drug for acute liver disease simultaneously supporting multiple failing organs. VS-01 targets 3 rare indications and received an Orphan Drug Designation in ALF. In addition, Versantis’ pipeline promises to improve patients’ outcome in other medical fields; VS-02 and VS-03 are developed for chronic liver diseases and for the treatment of drug intoxications, both representing large market opportunities and significant upsides for Versantis. | $5.1M / Series A / Mar 29, 2017 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Altus Capital Partners invest in?
Altus Capital Partners invests primarily in Health Care, Therapeutics and Pharmaceutical startups, most often at Series A stage. Most of the 1 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Altus Capital Partners?
Public channels for Altus Capital Partners include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Altus Capital Partners?
The team at Altus Capital Partners includes Joshua Tesoriero (Vice President), Nick DeMarco (Principal) and Tom Groh (Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
